Free Trial
NASDAQ:EWTX

Edgewise Therapeutics Q2 2024 Earnings Report

Edgewise Therapeutics logo
$14.30 -0.28 (-1.89%)
As of 03:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Edgewise Therapeutics EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Edgewise Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Edgewise Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

Edgewise Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Edgewise Therapeutics Earnings Headlines

Trump Knows Exactly What He's Doing
REVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.
See More Edgewise Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edgewise Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edgewise Therapeutics and other key companies, straight to your email.

About Edgewise Therapeutics

Edgewise Therapeutics (NASDAQ:EWTX), a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

View Edgewise Therapeutics Profile

More Earnings Resources from MarketBeat